Open AccessUtility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy
Author(s) -
Frank I. Lin,
Esther Mena Gonzalez,
Shivaani Kummar,
Khanh Do,
Joanna H. Shih,
S. S. Adler,
Karen Kurdziel,
Anita Ton,
Barış Türkbey,
Paula Jacobs,
Sudeep Bhattacharyya,
A. P. Chen,
Jerry M. Collins,
James H. Doroshow,
Peter L. Choyke,
Maria Liza Lindenberg
Publication year - 2016
Publication title -
european journal of nuclear medicine and molecular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.313
H-Index - 163
eISSN - 1619-7089
pISSN - 1619-7070
DOI - 10.1007/s00259-016-3561-8
Subject(s) - medicine , pharmacodynamics , estrogen receptor , positron emission tomography , tamoxifen , standardized uptake value , refractory (planetary science) , biomarker , imaging biomarker , nuclear medicine , magnetic resonance imaging , pharmacokinetics , breast cancer , radiology , cancer , chemistry , biochemistry , physics , astrobiology
Z-endoxifen is the most potent of the metabolites of tamoxifen, and has the potential to be more effective than tamoxifen because it bypasses potential drug resistance mechanisms attributable to patient variability in the expression of the hepatic microsomal enzyme CYP2D6. 18 F-FES is a positron emission tomography (PET) imaging agent which selectively binds to estrogen receptor alpha (ER-α) and has been used for non-invasive in vivo assessment of ER activity in tumors. This study utilizes 18 F-FES PET imaging as a pharmacodynamic biomarker in patients with ER+ tumors treated with Z-endoxifen.